UsAgainstAlzheimer’s Applauds Senate Alzheimer’s Investments, Calls for Lasting Research Protections
Washington, D.C. (November 16, 2026) – UsAgainstAlzheimer’s Chief Operating Officer Catherine Patterson issued the following statement in response to the Senate Appropriations Committee’s Fiscal Year (FY) 2027 Labor, Health and Human Services, Education, and Related Agencies (LHHS) appropriations bill:
“Once again, the Senate Appropriations Committee has prioritized ending Alzheimer’s disease. In its FY2027 LHHS bill, it includes a proposed increase of $100 million for Alzheimer’s disease and Alzheimer’s disease and related dementias research at the National Institutes of Health (NIH) and $50 million for the Centers for Disease Control and Prevention’s Alzheimer’s Disease Program — a significant increase of $8 million. Programs at both agencies are essential to advancing risk reduction, early detection, diagnosis, treatment, and care.
“Winning the fight against Alzheimer’s requires both groundbreaking biomedical research and strong public health programs that bring the latest science into communities across the country. NIH research is driving progress toward earlier detection, more effective treatments, and ultimately a cure, while CDC programs support state and local efforts to reduce dementia risk, promote brain health, and help families recognize and respond to the early signs of cognitive decline. We appreciate the Committee’s strong recognition and acknowledgment that both are essential to making meaningful progress against Alzheimer’s. Families need the promise of tomorrow’s breakthroughs and the tools to protect their brain health today.
“As the current continuing resolution expires on December 11, we call on the Congress to take all steps necessary to block the proposed changes to federal grantmaking regulations. It is imperative that Congress ensure that federal research funding decisions are made based on by scientific merit and patient need.”
###
About UsAgainstAlzheimer’s
UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations—the people who put the “Us” in UsAgainstAlzheimer’s.
Contact: Chantez Bailey, [email protected]